Polymorphonuclear leukocyte as a model of Ca++ and Mg++-dependent cellular activation. Effect of flunarizine.
Flunarizine, a calcium entry blocker drug, concentration-dependently inhibited FMLP and A23187-induced aggregation, enzyme release and superoxide anion generation from human granulocytes. A23187-dependent granulocyte aggregation was also studied in media devoided of Ca++ or Mg++. Flunarizine (2.4 x 10(-5) M) significantly affected not only Ca++-supported but also Mg++-sustained granulocyte aggregation. The inhibiting effect of the drug was reversed by increasing extracellular level of Ca++ (1.2 mM) or Mg++ (2 mM). In this "in vitro" model, the role of flunarizine as a specific Mg++ entry blocker was suggested.
D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002449:Cell Aggregation / Q000187:drug effects; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004798:Enzymes / Q000378:metabolism; D005444:Flunarizine; D006801:Humans; D066298:In Vitro Techniques; D008274:Magnesium / Q000494:pharmacology*; D008954:Models, Biological; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D013481:Superoxides / Q000378:metabolism
D002121:Calcium Channel Blockers; D004798:Enzymes; D013481:Superoxides; D000001:Calcimycin; D002936:Cinnarizine; D009240:N-Formylmethionine Leucyl-Phenylalanine; D008274:Magnesium; D005444:Flunarizine; D002118:Calcium